PATIENT ALERT CARD

Important Safety Information for Patients taking ZYNLONTA® ▼ (loncastuximab tesirine)

▼This medicinal product is subject to additional monitoring. This will allow the quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This patient alert card contains important safety information that you need to be aware of during treatment with ZYNLONTA®.

Please always keep this card with you and show this card to any doctor involved in your care.

- Treatment with ZYNLONTA can cause photosensitivity reactions through exposure to direct and indirect sunlight (such as through glass windows in vehicles and public transportation) including:
  - sunburn-like reactions such as skin peeling and irritation following exposure to light
  - itchy rash
  - blistering of skin
  - darker skin patches
  - irritation, swelling, pain
- **You must protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products during the entire treatment period.**
- If you experience any of these skin reactions, you should immediately call your treating doctor or seek emergency medical care.

www.sobi.com Preparation date: August 2025
NP-52831

Information for Healthcare Professionals

Please note that this patient is receiving treatment with ZYNLONTA® (loncastuximab tesirine) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

- ZYNLONTA can cause photosensitivity reactions, including sunburn-like reactions such as skin peeling and irritation following exposure to light, itchy rash, blistering of skin, darker skin patches irritation, swelling, pain
- ZYNLONTA should be withheld for severe (Grade 3) cutaneous reactions until resolution
- Dermatologic consultation should be considered
- Contact prescribing doctor (below) as soon as possible
- Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at *www.medicinesauthority.gov.mt/adrportal*,

  and sent by post or email to;
  P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000
  E: postlicensing.medicinesauthority@gov.mt

  Alternatively, Suspected Adverse Drug Reactions may be reported to the MAH;
  Tel.: +30 210 700 8245
  Email: PV.Medical.Info.GR@sobi.com
- For more information about ZYNLONTA, please refer to the full Summary of Product Characteristics or Email: medical.info.gr@sobi.com
- Medicines Authority RMM website archive: https://medicinesauthority.gov.mt/rmm

Zynlonta®
loncastuximab tesirine
for injection, for intravenous use - 10mg

Contact Details

Patient Name

Hospital where treated

Doctor name

Doctor's telephone number